Serum prostate-specific antigen is credited with dramatic advances in the early detection, screening, and management of men with prostatic carcinoma. There has been more than a twofold increase in the number of men diagnosed during the last decade, and prostate cancer has emerged as the most common non-skin cancer and the second leading cause of cancer death in men. This report summarizes the history and current status of prostate-specific antigen and other serum markers, incorporating consensus opinions from the Second International Consultation on Prostate Cancer held in Paris in June 1999
Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States...
Prostate cancer, is the most commonly diagnosed cancer in the United States and in many parts of the...
The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is no...
In the 6 years since the introduction of the first commercial immunoassays for prostate-specific ant...
Serum prostate markers, in particular prostate-specific antigen (PSA), have truly revolutionised all...
INTRODUCTION: Due to its universal applicability for early detection and prediction of cancer stage ...
This chapter mainly deals with biochemical aspects on prostate specific antigen (PSA) and its clinic...
An overview is given of serum and urine prostate cancer markers that are currently under investigati...
UNLABELLED: The introduction of total prostate specific antigen (total PSA) testing in blood has rev...
Contains fulltext : 47999schalken.pdf (publisher's version ) (Closed access)An ove...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
BACKGROUND. The purpose of the current study was to evaluate the effectiveness of a prostate carcino...
Prostate cancer is the second leading cause of cancer death among American men.1,2 Recent epidemiolo...
Prostate-specific antigen (PSA) is a glycoprotein pro-duced exclusively by prostatic tissue. PSA’s a...
After its isolation in 1979, the prostate-specific antigen focused the interest of the urologists an...
Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States...
Prostate cancer, is the most commonly diagnosed cancer in the United States and in many parts of the...
The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is no...
In the 6 years since the introduction of the first commercial immunoassays for prostate-specific ant...
Serum prostate markers, in particular prostate-specific antigen (PSA), have truly revolutionised all...
INTRODUCTION: Due to its universal applicability for early detection and prediction of cancer stage ...
This chapter mainly deals with biochemical aspects on prostate specific antigen (PSA) and its clinic...
An overview is given of serum and urine prostate cancer markers that are currently under investigati...
UNLABELLED: The introduction of total prostate specific antigen (total PSA) testing in blood has rev...
Contains fulltext : 47999schalken.pdf (publisher's version ) (Closed access)An ove...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
BACKGROUND. The purpose of the current study was to evaluate the effectiveness of a prostate carcino...
Prostate cancer is the second leading cause of cancer death among American men.1,2 Recent epidemiolo...
Prostate-specific antigen (PSA) is a glycoprotein pro-duced exclusively by prostatic tissue. PSA’s a...
After its isolation in 1979, the prostate-specific antigen focused the interest of the urologists an...
Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States...
Prostate cancer, is the most commonly diagnosed cancer in the United States and in many parts of the...
The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is no...